MEP0208A - Aptameri koji vezuje trombin sa visokim afininitetom - Google Patents

Aptameri koji vezuje trombin sa visokim afininitetom

Info

Publication number
MEP0208A
MEP0208A MEP-02/08A MEP0208A MEP0208A ME P0208 A MEP0208 A ME P0208A ME P0208 A MEP0208 A ME P0208A ME P0208 A MEP0208 A ME P0208A
Authority
ME
Montenegro
Prior art keywords
aptamers
thrombin
high affinity
bind thrombin
binding
Prior art date
Application number
MEP-02/08A
Other languages
Bosnian (bs)
English (en)
Inventor
John L Diener
Jess Wagner-Whyte
David Fontana
Original Assignee
Archemix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix Corp filed Critical Archemix Corp
Publication of MEP0208A publication Critical patent/MEP0208A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MEP-02/08A 2005-08-26 2006-08-23 Aptameri koji vezuje trombin sa visokim afininitetom MEP0208A (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71176805P 2005-08-26 2005-08-26
US80859006P 2006-05-26 2006-05-26
PCT/US2006/033092 WO2007025049A2 (en) 2005-08-26 2006-08-23 Aptamers that bind thrombin with high affinity

Publications (1)

Publication Number Publication Date
MEP0208A true MEP0208A (xx) 2010-02-10

Family

ID=37772390

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-2A ME00016B (me) 2005-08-26 2006-08-23 Aptameri koji vezuje trombin sa visokim afininitetom
MEP-02/08A MEP0208A (xx) 2005-08-26 2006-08-23 Aptameri koji vezuje trombin sa visokim afininitetom

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2008-2A ME00016B (me) 2005-08-26 2006-08-23 Aptameri koji vezuje trombin sa visokim afininitetom

Country Status (12)

Country Link
US (2) US7998939B2 (xx)
EP (1) EP1928505A4 (xx)
JP (1) JP2009508473A (xx)
KR (1) KR20080042091A (xx)
AU (1) AU2006283025A1 (xx)
BR (1) BRPI0614961A2 (xx)
CA (1) CA2617782A1 (xx)
EA (1) EA200800667A1 (xx)
IL (1) IL188797A0 (xx)
ME (2) ME00016B (xx)
RS (1) RS20080075A (xx)
WO (1) WO2007025049A2 (xx)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134069A2 (en) * 2007-04-26 2008-11-06 University Of Florida Research Foundation Anchored ligand agents
EP2304031A2 (en) * 2008-06-11 2011-04-06 Bionucleon S.r.l. Inhibition of hrp-3 using modified oligonucleotides
US20110275701A1 (en) * 2008-09-18 2011-11-10 Archemix Corp. Anti-thrombin aptamer formulations and methods for use
EP2497828A1 (en) 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
FR2983212A1 (fr) * 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
EP4219516A3 (en) 2012-07-13 2024-01-10 Wave Life Sciences Ltd. Chiral control
US10231993B2 (en) * 2013-06-27 2019-03-19 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
BR102013021701A2 (pt) 2013-08-26 2015-07-28 Univ São Paulo Usp Polinucleotídeos quimicamente modificados e processo de produção de polinucleotídeos quimicamente modificados
CN107002083A (zh) * 2014-07-31 2017-08-01 中央研究院 具拮抗pd‑1功能的适体分子于癌症治疗相关的应用
EP2982756A1 (en) 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamers for use against autoantibody-associated diseases
IL234246A0 (en) 2014-08-21 2014-11-30 Omrix Biopharmaceuticals Ltd Stabilized thrombin
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
EP4069363A1 (en) * 2019-12-04 2022-10-12 Duke University Methods for controlling extracorporeal membrane oxygenation (ecmo) coagulation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920561A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for thrombin and methods of use
US5756291A (en) * 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
BR9509985A (pt) * 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
AU2003217379A1 (en) * 2002-02-15 2003-09-09 Somalogic, Inc. Methods and reagents for detecting target binding by nucleic acid ligands
US20040197804A1 (en) * 2002-12-03 2004-10-07 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
CA2545006C (en) * 2003-12-12 2013-09-17 Saint Louis University Biosensors for detecting macromolecules and other analytes
CA2624686A1 (en) 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
EP1940861A4 (en) 2005-10-06 2009-09-09 Univ Delaware G-rich polynucleotide for the treatment of chorea huntingtone

Also Published As

Publication number Publication date
JP2009508473A (ja) 2009-03-05
EP1928505A4 (en) 2010-10-27
BRPI0614961A2 (pt) 2016-09-13
AU2006283025A1 (en) 2007-03-01
US7998939B2 (en) 2011-08-16
WO2007025049A2 (en) 2007-03-01
KR20080042091A (ko) 2008-05-14
IL188797A0 (en) 2008-08-07
RS20080075A (xx) 2009-07-15
CA2617782A1 (en) 2007-03-01
EA200800667A1 (ru) 2008-08-29
WO2007025049A3 (en) 2009-04-16
US20090221680A1 (en) 2009-09-03
US20120149764A1 (en) 2012-06-14
EP1928505A2 (en) 2008-06-11
ME00016B (me) 2010-06-10

Similar Documents

Publication Publication Date Title
RS20080075A (xx) Aptameri koji vezuju trombin sa visokim afinitetom
MY169746A (en) Dual variable domain immunoglobulin and uses thereof
TW200745163A (en) Peptides that block the binding of IgG to FcRn
PH12015500093A1 (en) Il-17 binding proteins
MX2009006471A (es) Anticuerpo anti especifico de linfopoyetina estromal timica de diseño.
WO2006033854A3 (en) Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
MX2010008688A (es) Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria.
MX2007009807A (es) Agentes terapeuticos de aptameros utiles en el tratamiento de trastornos relacionados con el complemento.
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
WO2008024188A3 (en) Dual variable domain immunoglobulin and uses thereof
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
MX2010011957A (es) Moleculas de union basadas en fibronectina mejoradas y usos de las mismas.
WO2010045388A3 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
WO2010033279A3 (en) Antibodies with altered binding to fcrn and methods of using same
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
EP2467167A4 (en) APTAMERS DIRECTED AGAINST A TISSUE FACTOR PATH INHIBITOR AND THEIR USE AS THERAPEUTIC AGENTS AGAINST BLEEDING DISORDERS
NO20091181L (no) Anti-C5AR-antistoffer med forbedrede egenskaper
WO2009102438A3 (en) Aptamer inhibitors of osteopontin and methods of use thereof
WO2006096222A3 (en) Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
ZA200801457B (en) Aptamers that bind thrombin with high affinity
WO2005113813A8 (en) Nucleic acid ligands specific to immunoglobulin e and their use as atopic disease therapeutics
AU2016202280A1 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
ZA200805051B (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL22R
WO2007035518A3 (en) Aptamers as agonists